ASP
  • COVID
    • INPATIENT >
      • CONSIDERATIONS & LABS
      • PAXLOVID
      • REMDESIVIR
      • OLUMIANT
      • ACTEMRA
      • STEROIDS
      • VTE
    • OUTPATIENT
  • Education
    • Bugs & Tips
    • Agents & Spectra
  • Guidelines
    • By Infection Type
    • Surgical Prophylaxis >
      • By Procedure
      • Dosing Guide
  • Formulary
  • Antibiogram
    • 2023 Inpatient
    • 2023 Outpatient
    • 2022 Inpatient
    • 2022 Outpatient
    • 2021 Inpatient
    • 2021 Outpatient
    • 2020 Inpatient
    • 2019 Inpatient
    • 2019 Outpatient
  • About
    • ASP Program
    • Stats & Data >
      • Recommendations
      • Pharmacy Data
      • MDR ORGANISMS
      • DDD/DOT
    • Contact

lAGEVRIO (MOLNUPIRAVIR)


NOTES

​​If a patient is hospitalized before completing the 5-day course of Lagevrio, the course may be completed in the hospital at the attending provider's discretion. The patient will need to provide the drug themselves as it is not available at GVH.​

MECHANISM & EVIDENCE

Picture

INDICATION & LIMITATIONS OF USE

Picture

CONTRAINDICATIONS, PRECAUTIONS & WARNINGS 

Picture

​ADVERSE EFFECTS

Picture

DOSING

Picture

COUNSELING

Picture

MEDWATCH REPORTING​

Picture

REFERENCES
  • COVID
    • INPATIENT >
      • CONSIDERATIONS & LABS
      • PAXLOVID
      • REMDESIVIR
      • OLUMIANT
      • ACTEMRA
      • STEROIDS
      • VTE
    • OUTPATIENT
  • Education
    • Bugs & Tips
    • Agents & Spectra
  • Guidelines
    • By Infection Type
    • Surgical Prophylaxis >
      • By Procedure
      • Dosing Guide
  • Formulary
  • Antibiogram
    • 2023 Inpatient
    • 2023 Outpatient
    • 2022 Inpatient
    • 2022 Outpatient
    • 2021 Inpatient
    • 2021 Outpatient
    • 2020 Inpatient
    • 2019 Inpatient
    • 2019 Outpatient
  • About
    • ASP Program
    • Stats & Data >
      • Recommendations
      • Pharmacy Data
      • MDR ORGANISMS
      • DDD/DOT
    • Contact